Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency.
OBJECTIVE
To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis.


METHODS
Retrospective chart review.


METHODS
AIDS clinic of inner-city hospital.


METHODS
Patients attending inhaled pentamidine clinic between 1989 and 1991.


METHODS
Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data.


RESULTS
Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p = 0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3.


CONCLUSIONS
Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.
Casale
L
L
Department of Medicine, Mount Sinai Medical Center, New York, NY.
Gold
H
H
Schechter
C
C
Naficy
A
A
Masci
J R
JR
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000280:Administration, Inhalation; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D010419:Pentamidine / Q000008:administration & dosage*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D012189:Retrospective Studies
D010419:Pentamidine